Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06041776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Apr 30, 2023 to Mar 28, 2023 Eligibility criteria shortened, about 155 words · Study title shortened, about 5 wordsv2 Show 2 more changesShow less
    • Eligibility criteria shortened, about 155 words
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.
Trial Details
NCT Number NCT06041776
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Enrollment 570 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov